NASDAQ · AHG

Akso Health Group ADS financials

$0.6910−5.47%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY26
Mar 31
FY25
Mar 31
FY24
Mar 31
FY23
Mar 31
FY22
Mar 31
Revenue$13.8M$14.8M$2.4M$13.2M$6.0M
Gross profit-$11.3K-$281.5K$122.1K$1.3M$605.1K
Gross margin−0.1%−1.9%5.1%9.6%10.1%
Operating income-$20.7M-$166.3M-$8.6M-$14.3M-$2.5M
Net income-$18.7M-$135.0M-$9.5M-$1.4M-$16.9M
Net margin−135.0%−913.4%−391.8%−10.3%−280.9%
Diluted EPS$-0.01$-0.16$-0.07$-0.02$-0.28
EBITDA-$1.6M-$1.8M-$8.6M-$14.3M-$2.5M
Operating cash flow-$12.8M$1.2M$1.4M-$3.3M-$8.6M
Free cash flow-$12.8M$1.0M$1.4M-$3.3M-$8.6M
Diluted shares2,168.1M855.3M141.5M68.6M59.6M

Balance sheet

Period endMar 31Mar 31Mar 31Mar 31Mar 31
Cash & equivalents$170.6K$176.2M$85.2M$7.9M$18.4M
Short-term investments$0.00$0.00$0.00$0.00$0.00
Total debt$350.5K$0.00$0.00$0.00$0.00
Total assets$189.6M$215.0M$142.0M$20.5M$62.8M
Total liabilities$8.7M$15.8M$3.6M$11.6M$50.5M
Shareholders' equity$180.9M$199.2M$138.4M$8.8M$12.3M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology